

Pancreatic Adenocarcinoma

New England Journal of Medicine

371, 2139-2141

DOI: [10.1056/nejmc1412266](https://doi.org/10.1056/nejmc1412266)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Advances in the Treatment of Metastatic Pancreatic Cancer. <i>Digestion</i> , 2015, 92, 175-184.	1.2	18
2	Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with ^{99m} Tc-Hynic-PEG-AE105. <i>Oncology Letters</i> , 2015, 10, 2253-2258.	0.8	2
3	miRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. <i>Biomarker Insights</i> , 2015, 10, BMI.S27679.	1.0	8
4	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 454.	0.7	17
5	The Quest for an Effective Treatment for an Intractable Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 283-306.	1.9	10
6	Mouse Models of Pancreatic Ductal Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 609-617.	0.9	14
7	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 1040-1048.	7.7	226
8	Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2015, 110, 1233-1239.	0.2	46
9	Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. <i>Cancer Discovery</i> , 2015, 5, 1247-1261.	7.7	178
10	Predicting a response to FOLFIRINOX in pancreatic cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv175-djv175.	3.0	1
11	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82
12	A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5475-5481.	1.0	3
13	High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6719-6726.	1.0	14
14	Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1155.	1.8	38
15	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. <i>Journal of Cancer</i> , 2016, 7, 1328-1339.	1.2	30
16	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1090.	1.8	15
17	The Expression and Prognostic Roles of MCMs in Pancreatic Cancer. <i>PLoS ONE</i> , 2016, 11, e0164150.	1.1	34
18	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. <i>Cancers</i> , 2016, 8, 45.	1.7	147

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. <i>International Journal of Medical Sciences</i> , 2016, 13, 902-913.	1.1	16
20	Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 1334-1344.	1.1	143
21	Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. <i>Nature Communications</i> , 2016, 7, 10770.	5.8	145
22	KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e157.	1.3	135
23	KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. <i>Medical Oncology</i> , 2016, 33, 32.	1.2	25
24	Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. <i>Nature Cell Biology</i> , 2016, 18, 549-560.	4.6	329
25	Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. <i>Journal of Biological Chemistry</i> , 2016, 291, 23208-23223.	1.6	53
26	Gemcitabine reduces MDSCs, tregs and TGF β -1 while restoring the teff/treg ratio in patients with pancreatic cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 282.	1.8	152
27	Recent insights into the function of autophagy in cancer. <i>Genes and Development</i> , 2016, 30, 1913-1930.	2.7	641
28	Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 770-781.	3.1	10
29	mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. <i>Cancer Research</i> , 2016, 76, 6911-6923.	0.4	63
30	Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. <i>Biomarkers in Medicine</i> , 2016, 10, 1197-1207.	0.6	22
31	Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. <i>Translational Oncology</i> , 2016, 9, 431-437.	1.7	42
32	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. <i>Medicine (United States)</i> , 2016, 95, e4006.	0.4	3
33	Therapeutic Approaches to RAS Mutation. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 165-174.	1.0	14
34	Phosphatidylinositol 3-Kinase. <i>Pancreas</i> , 2016, 45, 21-31.	0.5	11
35	Endoscopic ultrasound-guided choledochoduodenostomy with a lumen-apposing, self-expandable fully covered metal stent for palliative biliary drainage. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 79-85.	0.4	12
36	Preclinical models of pancreatic ductal adenocarcinoma. <i>Journal of Pathology</i> , 2016, 238, 197-204.	2.1	87

#	ARTICLE	IF	CITATIONS
37	Pancreatic adenocarcinoma. <i>Current Problems in Surgery</i> , 2016, 53, 107-154.	0.6	6
38	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1826-34.	3.3	492
39	Optimizing initial chemotherapy for metastatic pancreatic cancer. <i>Future Oncology</i> , 2016, 12, 1125-1133.	1.1	5
40	Model organoids provide new research opportunities for ductal pancreatic cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1014757.	0.3	52
41	Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer. <i>Tumor Biology</i> , 2016, 37, 3933-3938.	0.8	54
42	Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2017, 6, 463-470.	1.3	135
43	Dietary approach to attenuate human pancreatic cancer growth and migration with innocuousness. <i>Journal of Functional Foods</i> , 2017, 30, 303-312.	1.6	15
44	Tissue-specific tumorigenesis: context matters. <i>Nature Reviews Cancer</i> , 2017, 17, 239-253.	12.8	234
45	Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2040-2046.	0.7	30
46	Cardiorespiratory fitness and muscle strength in pancreatic cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 2797-2807.	1.0	27
47	Characterization of single lesion nonfunctioning pancreatic neuroendocrine carcinoma via computed tomography. <i>Oncology Letters</i> , 2017, 13, 2186-2190.	0.8	1
48	Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab -Paclitaxel Plus Gemcitabine. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 10-21.	2.0	21
49	Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor /c-Met/survivin regulated by P53/P21. <i>Experimental Cell Research</i> , 2017, 357, 79-87.	1.2	27
50	Current and future biomarkers for pancreatic adenocarcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769223.	0.8	62
51	Reviving the guardian of the genome: Small molecule activators of p53. , 2017, 178, 92-108.		59
52	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	3.0	116
53	ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 117, 1798-1809.	2.9	35
54	Commentary: Pancreatic cancer: is the worst to come?. <i>International Journal of Epidemiology</i> , 2017, 46, 1774-1775.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
56	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine. Pancreas, 2017, 46, 203-208.	0.5	24
57	Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma. Journal of Radiation Oncology, 2017, 6, 279-286.	0.7	2
58	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	51
59	A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. British Journal of Cancer, 2017, 117, 1846-1854.	2.9	80
60	Glycogen synthase kinase-3 β ablation limits pancreatitis-induced acinar-to-ductal metaplasia. Journal of Pathology, 2017, 243, 65-77.	2.1	29
61	Feasibility of real-time location systems in monitoring recovery after major abdominal surgery. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 5457-5462.	1.3	11
62	PET-MRI of the Pancreas and Kidneys. Current Radiology Reports, 2017, 5, 1.	0.4	0
63	Review of radiological classifications of pancreatic cancer with peripancreatic vessel invasion: are new grading criteria required?. Cancer Imaging, 2017, 17, 14.	1.2	16
64	PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Cellular and Molecular Life Sciences, 2017, 74, 4231-4243.	2.4	20
65	Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. American Journal of Pathology, 2017, 187, 146-155.	1.9	38
66	Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 1748-1759.	3.2	56
67	High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. Oncology Letters, 2017, 15, 2073-2078.	0.8	8
68	Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 3391-3397.	1.0	30
69	Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. International Journal of Molecular Sciences, 2017, 18, 1231.	1.8	31
70	The Drosophila Accessory Gland as a Model for Prostate Cancer and Other Pathologies. Current Topics in Developmental Biology, 2017, 121, 339-375.	1.0	39
71	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets and Therapy, 2017, Volume 10, 591-596.	1.0	22
72	Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Scientific Reports, 2018, 8, 3383.	1.6	29

#	ARTICLE	IF	CITATIONS
73	Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells. <i>Oncogene</i> , 2018, 37, 2757-2772.	2.6	61
74	Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1205-1217.	3.3	35
75	IFN- γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN- γ response. <i>Oncology Letters</i> , 2018, 15, 3760-3765.	0.8	22
76	Downregulation of 15 α -hydroxyprostaglandin dehydrogenase by interleukin-1 β from activated macrophages leads to poor prognosis in pancreatic cancer. <i>Cancer Science</i> , 2018, 109, 462-470.	1.7	33
77	Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b. <i>ACS Central Science</i> , 2018, 4, 71-80.	5.3	25
78	The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2018, 17, 62.	7.9	99
79	Liver resection for non-colorectal metastases. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018, 50, 113-116.	0.3	9
80	Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. <i>Cell Death and Disease</i> , 2018, 9, 468.	2.7	64
81	<sc>dCK</sc> negatively regulates the <sc>NRF</sc>2/<sc>ARE</sc> axis and <sc>ROS</sc> production in pancreatic cancer. <i>Cell Proliferation</i> , 2018, 51, e12456.	2.4	22
82	Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti- α -Prostate Stem Cell Antigen Cys-Diabody. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1398-1405.	2.8	40
83	The roles of ID-1 in human pancreatic ductal adenocarcinoma and the therapeutic effects of 2-methoxyestradiol. <i>Carcinogenesis</i> , 2018, 39, 728-737.	1.3	4
84	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. <i>Nano Letters</i> , 2018, 18, 2195-2208.	4.5	20
85	Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. <i>Investigational New Drugs</i> , 2018, 36, 20-27.	1.2	8
86	Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 8-20.	1.8	23
87	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2887-2894.	0.8	108
88	A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1-10.	0.6	39
89	Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib? a review of the open label phase III trial CONKO 005. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 399-402.	0.7	0
90	Out on the Fringe: Modulation of Notch Signaling by Glycosylation. , 2018, , 87-126.		0

#	ARTICLE	IF	CITATIONS
91	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	1.1	25
92	Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 291.	3.5	61
93	Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF- β -driven progression of pancreatic cancer. <i>International Journal of Oncology</i> , 2018, 54, 53-64.	1.4	15
94	Potential four miRNA signature associated with T ₁ /2 stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co-expression analysis. <i>Molecular Medicine Reports</i> , 2018, 19, 441-451.	1.1	3
95	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. <i>Frontiers in Endocrinology</i> , 2018, 9, 573.	1.5	24
96	The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. <i>Surgical Oncology</i> , 2018, 27, 688-694.	0.8	28
97	Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma. <i>Oncology Reports</i> , 2018, 40, 2628-2636.	1.2	20
98	Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF- κ B Signaling Pathway. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 413-422.	0.5	19
99	Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. <i>Annals of Surgical Oncology</i> , 2018, 25, 3492-3501.	0.7	4
100	G-CSF associates with neurogenesis and predicts prognosis and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 2767-2775.	0.9	4
101	Contribution of DNA repair xeroderma pigmentosum group D genotypes to pancreatic cancer risk in the Chinese Han population. <i>Genetics and Molecular Biology</i> , 2018, 41, 18-26.	0.6	4
102	Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-9.	0.5	5
103	Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. <i>Cancer Science</i> , 2018, 109, 2841-2851.	1.7	47
104	Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer. <i>Digestion</i> , 2018, 98, 209-216.	1.2	13
105	Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids. <i>Frontiers in Oncology</i> , 2018, 8, 114.	1.3	34
106	CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma. <i>Biological Research</i> , 2018, 51, 1.	1.5	40
107	Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment. <i>Cancer Letters</i> , 2018, 436, 22-27.	3.2	22
108	Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. <i>BMC Medicine</i> , 2018, 16, 125.	2.3	95

#	ARTICLE	IF	CITATIONS
109	Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1267-1275.	0.7	11
110	Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer. <i>BMC Cancer</i> , 2019, 19, 785.	1.1	20
111	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. <i>Science Signaling</i> , 2019, 12, .	1.6	46
112	High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 302.	3.5	53
113	Inhibition of Pancreatic Carcinoma Growth Through Enhancing γ -3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase. <i>Anticancer Research</i> , 2019, 39, 3651-3660.	0.5	20
114	Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts. <i>Frontiers in Oncology</i> , 2019, 9, 845.	1.3	9
115	Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. <i>BMC Cancer</i> , 2019, 19, 1020.	1.1	20
116	Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 451-464.	1.0	17
118	Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. <i>Molecular Medicine</i> , 2019, 25, 47.	1.9	34
119	Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2019, 9, 24.	1.1	7
120	Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, e193348.	2.2	30
121	Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. <i>Medical Oncology</i> , 2019, 36, 87.	1.2	12
122	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. <i>Cancers</i> , 2019, 11, 1330.	1.7	17
123	Impacting Pancreatic Cancer Therapy in Heterotypic <i>in Vitro</i> Organoids and <i>in Vivo</i> Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?. <i>Nano Letters</i> , 2019, 19, 7573-7587.	4.5	65
124	Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. <i>Journal of Oral Microbiology</i> , 2019, 11, 1563409.	1.2	93
125	Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 47.	3.5	63
126	Management of pancreatic head adenocarcinoma: From where to where?. <i>World Journal of Gastrointestinal Surgery</i> , 2019, 11, 143-154.	0.8	8
127	Identification of key pathways and candidate genes in pancreatic ductal adenocarcinoma using bioinformatics analysis. <i>Oncology Letters</i> , 2019, 17, 3751-3764.	0.8	8

#	ARTICLE	IF	CITATIONS
128	Blockade of integrin $\alpha 3$ attenuates human pancreatic cancer via inhibition of EGFR signalling. <i>Scientific Reports</i> , 2019, 9, 2793.	1.6	14
129	In search of the altering salivary proteome in metastatic breast and ovarian cancers. <i>FASEB BioAdvances</i> , 2019, 1, 191-207.	1.3	11
130	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. <i>Nature Medicine</i> , 2019, 25, 628-640.	15.2	476
131	Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers. <i>Theranostics</i> , 2019, 9, 1490-1509.	4.6	15
132	NMIIA promotes tumor growth and metastasis by activating the Wnt/ β -catenin signaling pathway and EMT in pancreatic cancer. <i>Oncogene</i> , 2019, 38, 5500-5515.	2.6	86
133	Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3878-3887.	1.6	22
134	Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 1489.	1.6	5
135	LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 75.	3.5	44
136	High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. <i>Carcinogenesis</i> , 2019, 40, 947-955.	1.3	19
137	The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 2042.	1.7	36
138	MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 281-288.	0.7	23
139	Pathogenesis of Pancreatic Cancer-Related Diabetes Mellitus. <i>Pancreas</i> , 2019, 48, 594-597.	0.5	7
140	Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 301-311.	1.9	64
141	Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. <i>Cancers</i> , 2019, 11, 57.	1.7	14
142	Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. <i>Cell Proliferation</i> , 2019, 52, e12514.	2.4	65
143	CYLD deficiency promotes pancreatic cancer development by causing mitotic defects. <i>Journal of Cellular Physiology</i> , 2019, 234, 9723-9732.	2.0	12
144	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	1.2	106
145	Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2020, 39, 308-321.	2.6	15

#	ARTICLE	IF	CITATIONS
146	Differentiation of focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma. <i>Abdominal Radiology</i> , 2020, 45, 1371-1386.	1.0	20
147	Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 15-26.	2.3	115
148	Liver Tropism in Cancer: The Hepatic Metastatic Niche. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037259.	2.9	35
149	Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 via AKT. <i>Cancer Biology and Therapy</i> , 2020, 21, 354-363.	1.5	18
150	Multicenter, randomized comparison of the diagnostic accuracy of 19-gauge stainless steel and nitinol-based needles for endoscopic ultrasound-guided fine-needle biopsy of solid pancreatic masses. <i>United European Gastroenterology Journal</i> , 2020, 8, 314-320.	1.6	4
151	Diagnostic delay does not influence survival of pancreatic cancer patients. <i>United European Gastroenterology Journal</i> , 2020, 8, 81-90.	1.6	20
152	Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 120-127.	0.5	31
153	GOLPH3 Promotes Cancer Growth by Interacting With STIP1 and Regulating Telomerase Activity in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 575358.	1.3	7
154	Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis. <i>Cancers</i> , 2020, 12, 2970.	1.7	16
155	Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 17817.	1.6	10
156	Metachronous hepatic resection for liver only pancreatic metastases. <i>Surgical Oncology</i> , 2020, 35, 169-173.	0.8	20
157	Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5023.	1.8	8
158	The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. <i>Scientific Reports</i> , 2020, 10, 12004.	1.6	6
159	Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. <i>Tumori</i> , 2021, 107, 030089162093779.	0.6	5
160	Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients. <i>World Journal of Surgical Oncology</i> , 2020, 18, 186.	0.8	15
161	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	2.9	69
162	Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1220.	1.3	33
163	Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 1965.	1.7	31

#	ARTICLE	IF	CITATIONS
182	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3018.	1.8	30
183	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2531.	1.8	56
184	Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2020, 10, 5241.	1.6	12
185	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1625-1645.	1.2	14
186	Non-neoplastic hepatopancreatobiliary lesions simulating malignancy: can we differentiate?. <i>Insights Into Imaging</i> , 2020, 11, 21.	1.6	2
187	Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 21-30.	2.0	19
188	High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF1. <i>EMBO Reports</i> , 2020, 21, e48780.	2.0	29
189	MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma: A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 38-48.	1.9	29
190	Neurotensin receptor 1 signaling promotes pancreatic cancer progression. <i>Molecular Oncology</i> , 2021, 15, 151-166.	2.1	17
191	Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. <i>Molecular Therapy</i> , 2021, 29, 775-787.	3.7	8
192	Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 719-726.	1.4	3
193	Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. <i>Cancer Discovery</i> , 2021, 11, 446-479.	7.7	97
194	The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 373-391.	1.2	8
195	Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101541.	0.7	8
196	Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188409.	3.3	144
197	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2312-2322.	0.7	5
198	Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features. <i>Bioengineered</i> , 2021, 12, 3593-3602.	1.4	10
200	Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation. <i>Theranostics</i> , 2021, 11, 1672-1689.	4.6	3

#	ARTICLE	IF	CITATIONS
201	Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 3634-3645.	2.6	5
202	Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 672-684.	1.1	21
203	The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. <i>ESMO Open</i> , 2021, 6, 100010.	2.0	16
204	Immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 751-759.	0.8	18
205	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1725-1741.	2.8	53
206	Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. <i>Aging</i> , 2021, 13, 6041-6054.	1.4	14
207	Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. <i>Cancers</i> , 2021, 13, 1608.	1.7	12
208	SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. <i>Genomics</i> , 2021, 113, 827-842.	1.3	27
209	MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma. <i>Stresses</i> , 2021, 1, 30-47.	1.8	10
210	Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. <i>BMC Surgery</i> , 2021, 21, 110.	0.6	2
211	Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. <i>Npj Precision Oncology</i> , 2021, 5, 25.	2.3	14
212	Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants. <i>EMBO Journal</i> , 2021, 40, e107206.	3.5	15
213	Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 1851.	1.7	2
214	Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1283-1295.	1.5	15
215	The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. <i>Frontiers in Oncology</i> , 2021, 11, 640863.	1.3	14
216	Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis. <i>World Journal of Gastroenterology</i> , 2021, 27, 1993-2014.	1.4	14
217	PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. <i>PLoS ONE</i> , 2021, 16, e0251656.	1.1	10
218	MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 340-355.	2.0	13

#	ARTICLE	IF	CITATIONS
219	Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1911-1921.	1.0	7
220	The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6374.	1.8	12
221	Radiomic Features at CT Can Distinguish Pancreatic Cancer from Noncancerous Pancreas. <i>Radiology Imaging Cancer</i> , 2021, 3, e210010.	0.7	22
222	Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. <i>Translational Oncology</i> , 2021, 14, 101090.	1.7	21
223	Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. <i>World Journal of Clinical Cases</i> , 2021, 9, 5398-5407.	0.3	4
225	Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples. <i>Endoscopy</i> , 2022, 54, 503-508.	1.0	5
226	Pancreatic Cancer and Immunotherapy: A Clinical Overview. <i>Cancers</i> , 2021, 13, 4138.	1.7	49
227	MTAP Deficiency Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting <i>De Novo</i> Purine Synthesis and Glycolysis in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 4964-4980.	0.4	15
228	A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 691605.	2.2	25
229	Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 369-382.	2.3	26
230	Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10219.	1.8	14
231	LINC00941 promotes glycolysis in pancreatic cancer by modulating the Hippo pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 280-294.	2.3	28
232	Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. <i>Aging</i> , 2021, 13, 3386-3404.	1.4	14
233	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. <i>Journal of Personalized Medicine</i> , 2021, 11, 83.	1.1	8
234	Molecular subtypes of pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 207-220.	8.2	573
237	A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma. <i>Medical Science Monitor</i> , 2019, 25, 3683-3691.	0.5	5
238	Curcumin Modulates Pancreatic Adenocarcinoma Cell-Derived Exosomal Function. <i>PLoS ONE</i> , 2015, 10, e0132845.	1.1	95
239	Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. <i>PLoS ONE</i> , 2017, 12, e0182855.	1.1	51

#	ARTICLE	IF	CITATIONS
240	Cancer Care Quality: Current State and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e337-e341.	1.8	2
241	The role of metabolic adaptation to nutrient stress in pancreatic cancer. <i>Cell Stress</i> , 2018, 2, 332-339.	1.4	19
242	Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numb1. <i>Oncotarget</i> , 2016, 7, 58367-58380.	0.8	73
243	Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. <i>Oncotarget</i> , 2016, 7, 62460-62473.	0.8	27
244	Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. <i>Oncotarget</i> , 2016, 7, 71635-71650.	0.8	60
245	Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. <i>Oncotarget</i> , 2017, 8, 26344-26355.	0.8	16
246	A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 24250-24261.	0.8	8
247	Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 62953-62961.	0.8	15
248	Reciprocal regulation of DGCR5 and miR-320a affects the cellular malignant phenotype and 5-FU response in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90868-90878.	0.8	26
249	Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein involvement: Chinese center experience. <i>Oncotarget</i> , 2017, 8, 77883-77896.	0.8	7
250	<i>In vitro</i> , <i>in vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 6952-6967.	0.8	19
251	PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells. <i>Oncotarget</i> , 2016, 7, 7801-7815.	0.8	22
252	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. <i>Annals of Translational Medicine</i> , 2016, 4, 165-165.	0.7	19
253	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
254	Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: A study based on differentially expressed circRNAs, lncRNAs, miRNAs and mRNAs. <i>International Journal of Oncology</i> , 2019, 54, 600-626.	3.9	33
255	Lewis antigen-negative pancreatic cancer: An aggressive subgroup. <i>International Journal of Oncology</i> , 2020, 56, 900-908.	1.4	21
256	Targeting TM4SF5 with anti-TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells. <i>Oncology Letters</i> , 2020, 19, 641-650.	0.8	3
257	Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 1253-1263.	1.3	15

#	ARTICLE	IF	CITATIONS
258	Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. <i>Cancer Research and Treatment</i> , 2017, 49, 1022-1032.	1.3	9
259	Pancreatic adenocarcinoma with early esophageal metastasis: A case report and review of literature. <i>World Journal of Clinical Oncology</i> , 2020, 11, 83-90.	0.9	3
260	Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. <i>Ageing</i> , 2021, 13, 22830-22842.	1.4	13
261	Optimizing In Situ Vaccination During Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 711078.	1.3	5
262	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. <i>Cancers</i> , 2021, 13, 5059.	1.7	39
263	The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. <i>Cancers</i> , 2021, 13, 4979.	1.7	9
264	Pancreatic Cancer Stem Cells. , 2015, , 247-271.		0
265	Modulation of Gene Expression During Stages of Liver Colonization by Pancreatic Cancer in a Rat Model. , 0, , .		0
268	PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma. <i>Oncology Letters</i> , 2020, 19, 121-126.	0.8	2
269	Hepatocyte Growth Factor and Macrophage-stimulating Protein Hinge Analogs to Treat Pancreatic Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 782-795.	0.8	1
270	DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	10
274	Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2638-48.	0.5	29
275	NEAT1 regulates pancreatic cancer cell growth, invasion and migration through microRNA-335-5p/c-met axis. <i>American Journal of Cancer Research</i> , 2016, 6, 2361-2374.	1.4	30
276	Establishment of pancreatic cancer patient-derived xenograft models and comparison of the differences among the generations. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 3128-3139.	0.0	7
277	Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 719390.	1.8	12
278	Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 4912-4922.	1.3	6
279	The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 311-322.	1.7	5
280	Effects of toluidine blue O and methylene blue on growth and viability of pancreatic cancer cells. <i>Drug Development Research</i> , 2022, , .	1.4	3

#	ARTICLE	IF	CITATIONS
281	Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism. <i>Oncogene</i> , 2022, 41, 1468-1481.	2.6	4
282	Aminopyridine analogs selectively target metastatic pancreatic cancer. <i>Oncogene</i> , 2022, 41, 1518-1525.	2.6	2
283	Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma – Current Options and the Future Impact of Molecular Biological Profiling. <i>Visceral Medicine</i> , 2022, 38, 1-3.	0.5	0
284	Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A. <i>Oncology Research and Treatment</i> , 2022, 45, 291-298.	0.8	7
285	Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head. <i>Cancers</i> , 2022, 14, 850.	1.7	2
286	Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 816517.	1.8	4
287	Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. <i>Frontiers in Immunology</i> , 2022, 13, 799026.	2.2	4
288	LEM domain containing 1 promotes pancreatic cancer growth and metastasis by p53 and mTORC1 signaling pathway. <i>Bioengineered</i> , 2022, 13, 7771-7784.	1.4	3
289	Nickel's Role in Pancreatic Ductal Adenocarcinoma: Potential Involvement of microRNAs. <i>Toxics</i> , 2022, 10, 148.	1.6	5
291	LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). <i>Annals of Translational Medicine</i> , 2022, 10, 317-317.	0.7	3
292	B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 867902.	2.2	8
293	TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 24.	2.7	14
294	Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets. <i>Human Molecular Genetics</i> , 2022, 31, 1705-1719.	1.4	12
295	Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. <i>Science Advances</i> , 2021, 7, eabh2724.	4.7	27
296	Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. <i>In Vivo</i> , 2022, 36, 57-62.	0.6	5
297	Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma. <i>Archives of Toxicology</i> , 2022, 96, 467-485.	1.9	6
298	T cells in pancreatic cancer stroma. <i>World Journal of Gastroenterology</i> , 2021, 27, 7956-7968.	1.4	26
299	Challenges and Opportunities Associated With Platelets in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 850485.	1.3	4

#	ARTICLE	IF	CITATIONS
300	Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Recurrence Rate. <i>Digestive Surgery</i> , 2022, 39, 191-200.	0.6	2
301	Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis. <i>Pathology Research and Practice</i> , 2022, 234, 153911.	1.0	5
302	The HDL particle composition determines its antitumor activity in pancreatic cancer. <i>Life Science Alliance</i> , 2022, 5, e202101317.	1.3	10
303	Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. <i>Endoscopy International Open</i> , 2022, 10, E910-E916.	0.9	0
304	Integrin β 1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. <i>Cancers</i> , 2022, 14, 3377.	1.7	8
305	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	3.2	45
307	Prognostic Significance of Initial Absolute Lymphocyte Count in Adjuvant Radiotherapy for Pancreatic Adenocarcinoma. <i>Biomedicines</i> , 2022, 10, 2190.	1.4	0
308	Management of Resectable and Borderline Resectable Disease: Radiation Oncology. , 2022, , 153-171.		0
309	Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1147-1160.	1.0	1
310	A multi-omics machine learning framework in predicting the recurrence and metastasis of patients with pancreatic adenocarcinoma. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
311	Temporal Association of Total Serum Cholesterol and Pancreatic Cancer Incidence. <i>Nutrients</i> , 2022, 14, 4938.	1.7	6
312	Neoadjuvant chemotherapy and radiotherapy outcomes in <sc>borderlineâ€resectable</sc> and <sc>locallyâ€advanced</sc> pancreatic cancer patients. <i>Cancer Medicine</i> , 2023, 12, 7713-7723.	1.3	3
313	Drug Discovery Platform Using Organoids. <i>Journal of Digestive Cancer Reports</i> , 2022, 10, 82-91.	0.0	0
314	Diagnostic and Prognostic Role of Extracellular Vesicles in Pancreatic Cancer: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2023, 24, 885.	1.8	8
315	Insulin promotes the proliferation and migration of pancreatic cancer cells by up-regulating the expression of PLK1 through the PI3K/AKT pathway. <i>Biochemical and Biophysical Research Communications</i> , 2023, 648, 21-27.	1.0	4
316	Knockout of ENO1 leads to metabolism reprogramming and tumor retardation in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
318	The Gut Microbiome and Pancreatic Cancer Development and Treatment. <i>Cancer Journal (Sudbury)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	3
319	Integrated In Silico Analysis of Proteogenomic and Drug Targets for Pancreatic Cancer Survival. <i>Methods in Molecular Biology</i> , 2023, , 273-282.	0.4	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------